#sarscov2 — Public Fediverse posts

Gut microbial allies and adversaries in #SARSCoV2 infection.

#COVID19 patients show reduced gut diversity. Specific commensals, especially Bacteroides uniformis, may help modulate immune responses.

#OpenAccess #Covid #microbiota #microbiology

https://davidojcius.blogspot.com/2026/09/gut-microbiota-signatures-and-immune.html

@edsuom

I was only saying to someone yesterday that at one point very early on, the world had the chance to eliminate #SarsCOV2

We had an unprecedented global connection and we blew it.

Yes, you're so right, they just aren't quite the same and it's awful to see.

#COVID19 #COVIDisNOTover

@edsuom

I was only saying to someone yesterday that at one point very early on, the world had the chance to eliminate #SarsCOV2

We had an unprecedented global connection and we blew it.

Yes, you're so right, they just aren't quite the same and it's awful to see.

#COVID19 #COVIDisNOTover

@edsuom

I was only saying to someone yesterday that at one point very early on, the world had the chance to eliminate #SarsCOV2

We had an unprecedented global connection and we blew it.

Yes, you're so right, they just aren't quite the same and it's awful to see.

#COVID19 #COVIDisNOTover

@edsuom

I was only saying to someone yesterday that at one point very early on, the world had the chance to eliminate #SarsCOV2

We had an unprecedented global connection and we blew it.

Yes, you're so right, they just aren't quite the same and it's awful to see.

#COVID19 #COVIDisNOTover

@edsuom

I was only saying to someone yesterday that at one point very early on, the world had the chance to eliminate #SarsCOV2

We had an unprecedented global connection and we blew it.

Yes, you're so right, they just aren't quite the same and it's awful to see.

#COVID19 #COVIDisNOTover

New Data Shows Covid Still On The Rise In Many States!!

#COVID19 #SARSCoV2 #Pandemic #CovidIsNotOver #CovidIsAirborne #H5N1 #Measles #WhoopingCough #RSV #Norovirus #Tuberculosis #Polio #Mpox #MaskUp #N95 #KeepMasksInHealthcare

https://www.youtube.com/watch?v=rcUuzP1Gch4

New Data Shows Covid Still On The Rise In Many States!!

#COVID19 #SARSCoV2 #Pandemic #CovidIsNotOver #CovidIsAirborne #H5N1 #Measles #WhoopingCough #RSV #Norovirus #Tuberculosis #Polio #Mpox #MaskUp #N95 #KeepMasksInHealthcare

https://www.youtube.com/watch?v=rcUuzP1Gch4

Covid Cases Are Once Again Exploding Around The World!!

#COVID19 #SARSCoV2 #Pandemic #CovidIsNotOver #CovidIsAirborne #H5N1 #Measles #WhoopingCough #RSV #Norovirus #Tuberculosis #Polio #Mpox #MaskUp #N95 #KeepMasksInHealthcare

https://www.youtube.com/watch?v=9qYdZfPRo1s

Covid Cases Are Once Again Exploding Around The World!!

#COVID19 #SARSCoV2 #Pandemic #CovidIsNotOver #CovidIsAirborne #H5N1 #Measles #WhoopingCough #RSV #Norovirus #Tuberculosis #Polio #Mpox #MaskUp #N95 #KeepMasksInHealthcare

https://www.youtube.com/watch?v=9qYdZfPRo1s

Could We Be Headed Into Uncharted Territory With Covid?

#COVID19 #SARSCoV2 #Pandemic #CovidIsNotOver #CovidIsAirborne #H5N1 #Measles #WhoopingCough #RSV #Norovirus #Tuberculosis #Polio #Mpox #MaskUp #N95 #KeepMasksInHealthcare

https://www.youtube.com/watch?v=m1fcIZ-YD-4

Could We Be Headed Into Uncharted Territory With Covid?

#COVID19 #SARSCoV2 #Pandemic #CovidIsNotOver #CovidIsAirborne #H5N1 #Measles #WhoopingCough #RSV #Norovirus #Tuberculosis #Polio #Mpox #MaskUp #N95 #KeepMasksInHealthcare

https://www.youtube.com/watch?v=m1fcIZ-YD-4

#FYI #USA #MicrobeTV #ThisWeekInVirology #DanielGriffin #VincentRacaniello #MASA #MakeAmericaSaneAgain #infectiousdiseases #vaccinate #vaccines #covid19 #covid #sarscov2 #LongCovid #shingles #cyclospora #cyclosporiasis #Ecoli #screwworm #malaria #measles #RSV #influenza #flu

#TWIV 1354 clinical update 06.Sep.2026

https://youtu.be/vc7X6TXXKCI

https://www.europesays.com/cz/204331/ Epidemie z 9. patra hotelu. Jediný lékař nakazil tisíce lidí na celém světě #COVID19 #Headlines #HlavníUdálosti #Infekce #News #Pandemie #SARSCoV2 #TopNews #TopStories #UdálostiDne #Zprávy

#Kinder haben es in Deutschland weiterhin schwer, eine #Impfung gegen #COVID19 zu erhalten:

Nur «als Einzeldosis-Durchstechflasche im 10er-Pack verfügbar» und mit «erforderlicher Ultratiefkühl-Logistik über spezialisierte Vertriebsapotheken».

https://www.kbv.de/praxis/tools-und-services/praxisnachrichten/2026/08-27/arztpraxen-koennen-ab-september-neuen-covid-19-kinderimpfstoff-bestellen-geaendertes-bestellverfahren

OK, immerhin gibt es in Deutschland überhaupt den Kinderimpfstoff, anders als in der Schweiz … 🤢

#ProtectTheKids #Coronavirus #SARSCoV2 #Pandemie

#Kinder haben es in Deutschland weiterhin schwer, eine #Impfung gegen #COVID19 zu erhalten:

Nur «als Einzeldosis-Durchstechflasche im 10er-Pack verfügbar» und mit «erforderlicher Ultratiefkühl-Logistik über spezialisierte Vertriebsapotheken».

https://www.kbv.de/praxis/tools-und-services/praxisnachrichten/2026/08-27/arztpraxen-koennen-ab-september-neuen-covid-19-kinderimpfstoff-bestellen-geaendertes-bestellverfahren

OK, immerhin gibt es in Deutschland überhaupt den Kinderimpfstoff, anders als in der Schweiz … 🤢

#ProtectTheKids #Coronavirus #SARSCoV2 #Pandemie

#Kinder haben es in Deutschland weiterhin schwer, eine #Impfung gegen #COVID19 zu erhalten:

Nur «als Einzeldosis-Durchstechflasche im 10er-Pack verfügbar» und mit «erforderlicher Ultratiefkühl-Logistik über spezialisierte Vertriebsapotheken».

https://www.kbv.de/praxis/tools-und-services/praxisnachrichten/2026/08-27/arztpraxen-koennen-ab-september-neuen-covid-19-kinderimpfstoff-bestellen-geaendertes-bestellverfahren

OK, immerhin gibt es in Deutschland überhaupt den Kinderimpfstoff, anders als in der Schweiz … 🤢

#ProtectTheKids #Coronavirus #SARSCoV2 #Pandemie

#Kinder haben es in Deutschland weiterhin schwer, eine #Impfung gegen #COVID19 zu erhalten:

Nur «als Einzeldosis-Durchstechflasche im 10er-Pack verfügbar» und mit «erforderlicher Ultratiefkühl-Logistik über spezialisierte Vertriebsapotheken».

https://www.kbv.de/praxis/tools-und-services/praxisnachrichten/2026/08-27/arztpraxen-koennen-ab-september-neuen-covid-19-kinderimpfstoff-bestellen-geaendertes-bestellverfahren

OK, immerhin gibt es in Deutschland überhaupt den Kinderimpfstoff, anders als in der Schweiz … 🤢

#ProtectTheKids #Coronavirus #SARSCoV2 #Pandemie

#Kinder haben es in Deutschland weiterhin schwer, eine #Impfung gegen #COVID19 zu erhalten:

Nur «als Einzeldosis-Durchstechflasche im 10er-Pack verfügbar» und mit «erforderlicher Ultratiefkühl-Logistik über spezialisierte Vertriebsapotheken».

https://www.kbv.de/praxis/tools-und-services/praxisnachrichten/2026/08-27/arztpraxen-koennen-ab-september-neuen-covid-19-kinderimpfstoff-bestellen-geaendertes-bestellverfahren

OK, immerhin gibt es in Deutschland überhaupt den Kinderimpfstoff, anders als in der Schweiz … 🤢

#ProtectTheKids #Coronavirus #SARSCoV2 #Pandemie

#covid19 #covid #sarscov2 #cancer #lung #lungCancer #virus #viralinfection

Original paywalled article

Qian et al. 11 March 2026, Cell pre-print

Respiratory viral infections prime accelerated lung cancer growth

doi: 10.1101/2025.09.02.672566

Open access author's manuscript:
https://pmc.ncbi.nlm.nih.gov/articles/PMC12424724/

zu reden. Die nicht mehr laut sein können. #NichtGenesen

Wir können mit #Behinderungen geboren werden oder, im Laufe eines Lebens, behindert werden. Auch schon körperliche Einschränkungen zählen hierzu.

Aktuell registrieren wir eine steigende Zahl von #LongCovid (und ja, umfasst über 200 Symptome), #PEM, #pots, #Diabetes, #Herzinfarkten, #Schlaganfällen, #MECFS, #hashimoto und anderen #Autoimmunerkrankungen. Ursache dafür ist der neuartige #Corona #SARSCoV2, der ja immer noch pandemisch ist.

Trennungen zwischen Hirnstamm und Kleinhirn" findet ihr unter https://www.change.org/p/hygiene-neu-denken-saubere-innenraumluft-und-konsequente-schutzma%C3%9Fnahmen/u/33431064

#CleanAir #SaubereLuft #MaskUp #FFP2Masken #Corona #SARSCoV2 #h5n1 #Influenza #RSV #ImpfenSchützt #Masern #measle #norovirus #rotavírus #tuberkulosis #tuberkulose

«Die Ukraine hat den Höhepunkt der Inzidenz von Influenza und Covid überschritten - Gesundheitsministerium»

https://ukraine-nachrichten.de/ukraine-h%C3%B6hepunkt-inzidenz-influenza-covid-%C3%BCberschritten-gesundheitsministerium_24708?mtm_source=mastodon&mtm_medium=social&mtm_campaign=ma

#Ukraine #Coronavirus #Covid19 #Covid19Pandemie #Czernowitz #Epidemien #Gesundheitsministerium #IwanoFrankiwsk #Kiew #Kinder #Kirowograd #Kirowohrad #Krankheiten #Kyjiw #Lwiw #Odessa #Pandemie #Poltawa #Riwne #SarsCov2 #Schytomyr #Sumy #Ternopil #Transkarpaten #Tscherkassy #Tschernihiw #Tscherniwzi #Winnyzja #Wolhynien

«Das Gesundheitsministerium hat eine alarmierende Entwicklung der Grippe und des Coronavirus bekannt gegeben»

https://ukraine-nachrichten.de/gesundheitsministerium-eine-alarmierende-entwicklung-grippe-coronavirus-bekannt-gegeben_24516?mtm_source=mastodon&mtm_medium=social&mtm_campaign=ma

#Ukraine #Coronavirus #Covid19 #Covid19Pandemie #Epidemien #Gesundheitsminister #Gesundheitsministerium #Krankheiten #Pandemie #SarsCov2 #WiktorLjaschko

#Coronavirus Disease Research #References (by AMEDEO, December 7 ’24)

1. VASSILOPOULOS S, Mylonakis E
   After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y.
   Ann Intern Med. 2024 Dec 3. doi: 10.7326/ANNALS-24-02887.
   PubMed         Abstract available

   Antiviral Res

2. SCHRELL L, Fuchs HL, Dickmanns A, Scheibner D, et al
   Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine.
   Antiviral Res. 2024 Dec 3:106046. doi: 10.1016/j.antiviral.2024.106046.
   PubMed         Abstract available

   Br J Anaesth

3. SPARLING JL, Chitilian HV, Korn E, Alfille PH, et al
   Induction of anaesthesia and airway management in patients with severe tracheal stenosis: a single-centre retrospective study.
   Br J Anaesth. 2024 Dec 4:S0007-0912(24)00667-6. doi: 10.1016/j.bja.2024.
   PubMed        

   Emerg Infect Dis

4. HASSAN AM, Muhlemann B, Al-Subhi TL, Rodon J, et al
   Ongoing Evolution of Middle East Respiratory Syndrome Coronavirus, Saudi Arabia, 2023-2024.
   Emerg Infect Dis. 2024;31.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

5. KIM T, Moehring RW, Turner NA, Ashley ED, et al
   Long-term trends in the incidence of hospital-acquired carbapenem-resistant Enterobacterales and antimicrobial utilization in a network of community hospitals in the Southeastern United States from 2013 to 2023.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-7. doi: 10.1017/ice.2024.
   PubMed         Abstract available
6. USIAK S, Aslam A, Yan J, Madhavappallil J, et al
   Utility of post-admission SARS-CoV-2 serial testing in hospitalized patients with cancer.
   Infect Control Hosp Epidemiol. 2024 Dec 3:1-3. doi: 10.1017/ice.2024.
   PubMed         Abstract available
7. PASSARETTI CL, Bischoff W, Chan J, Diekema DJ, et al
   Respiratory equality: let’s stop playing favorites with COVID-19 in the healthcare setting.
   Infect Control Hosp Epidemiol. 2024 Dec 4:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

8. IP B, Pan S, Yao A, Lau L, et al
   COVID-19 vaccination and cerebral small vessel disease progression – A prospective cohort study.
   Int J Infect Dis. 2024 Dec 3:107324. doi: 10.1016/j.ijid.2024.107324.
   PubMed         Abstract available

   J Infect

9. PENG Y, Shen H, Zhang Y, Zeng S, et al
   A comprehensive pan-cancer analysis of SARS-CoV-2-related cancer malignancy: COVID-19 infection shapes a dynamic immune microenvironment and affects the prognosis.
   J Infect. 2024 Nov 30:106364. doi: 10.1016/j.jinf.2024.106364.
   PubMed        

   J Med Virol

10. ZWYGART AC, Medaglia C, Zhu Y, Bart Tarbet E, et al
    Development of Broad-Spectrum beta-Cyclodextrins-Based Nanomaterials Against Influenza Viruses.
    J Med Virol. 2024;96:e70101.
    PubMed         Abstract available
11. STICH M, Magalhaes VG, Burger F, Garbade SF, et al
    Elevated Soluble ACE2 Activity in Children and Adults After SARS-CoV-2 Exposure Irrespective of Laboratory-Confirmed Infection.
    J Med Virol. 2024;96:e70098.
    PubMed         Abstract available
12. MAIMAITI M, Kong L, Yu Q, Wang Z, et al
    Analytical Performance of a Novel Nanopore Sequencing for SARS-CoV-2 Genomic Surveillance.
    J Med Virol. 2024;96:e70108.
    PubMed         Abstract available

    J Virol

13. ZUO F, Cao Y, Sun R, Wang Q, et al
    Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants.
    J Virol. 2024 Dec 4:e0174024. doi: 10.1128/jvi.01740.
    PubMed        
14. ZHANG Y, Zhang N, Zhang Y, Li Y, et al
    Potassium molybdate blocks APN-dependent coronavirus entry by degrading receptor via PIK3C3-mediated autophagy.
    J Virol. 2024 Dec 6:e0144924. doi: 10.1128/jvi.01449.
    PubMed         Abstract available

    JAMA

15. ANDERER S
    CDC Recommends Second COVID-19 Vaccine Dose for Older Adults.
    JAMA. 2024 Dec 6. doi: 10.1001/jama.2024.24258.
    PubMed        

    Nature

16. KUDIABOR H
    Virtual lab powered by ‘AI scientists’ super-charges biomedical research.
    Nature. 2024 Dec 4. doi: 10.1038/d41586-024-01684.
    PubMed        

    Science

17. KAISER J
    Trump picks an ‘outsider’ and NIH critic to lead agency.
    Science. 2024;386:1080-1081.
    PubMed         Abstract available

#betacoronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2 #science

#Coronavirus Disease Research #References (by AMEDEO, December 1 ’24)

1. MCGOVERN-GOOCH KR, Mani N, Gotchev D, Ardzinski A, et al
   Biological characterization of AB-343, a novel and potent SARS-CoV-2 M(pro) inhibitor with pan-coronavirus activity.
   Antiviral Res. 2024;232:106038.
   PubMed         Abstract available
2. AMIN MR, Anwar KN, Ashraf MJ, Ghassemi M, et al
   Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.
   Antiviral Res. 2024;232:106041.
   PubMed         Abstract available
3. GENG X, Zhu Y, Gao Y, Chong H, et al
   Development of lipopeptide-based HIV-1/2 fusion inhibitors targeting the gp41 pocket site with a new design strategy.
   Antiviral Res. 2024 Nov 23:106042. doi: 10.1016/j.antiviral.2024.106042.
   PubMed         Abstract available

   BMJ

4. ZERAATKAR D, Ling M, Kirsh S, Jassal T, et al
   Interventions for the management of long covid (post-covid condition): living systematic review.
   BMJ. 2024;387:e081318.
   PubMed         Abstract available

   Clin Infect Dis

5. TOWNSEND JP, Hassler HB, Dornburg A
   Optimal Annual COVID-19 Vaccine Boosting Dates Following Previous Booster Vaccination or Breakthrough Infection.
   Clin Infect Dis. 2024 Nov 26:ciae559. doi: 10.1093.
   PubMed         Abstract available
6. FAUCI AS, Folkers GK
   HIV/AIDS and COVID-19: Shared Lessons from Two Pandemics.
   Clin Infect Dis. 2024 Nov 27:ciae585. doi: 10.1093.
   PubMed         Abstract available
7. LEWIS NM, Harker EJ, Grant LB, Zhu Y, et al
   Benefit of early oseltamivir therapy for adults hospitalized with influenza A: an observational study.
   Clin Infect Dis. 2024 Nov 28:ciae584. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

8. SANDS KE, Blanchard EJ, Hasse A, Korwek K, et al
   Risk factors for healthcare-associated infection among patients hospitalized with COVID-19 infection.
   Infect Control Hosp Epidemiol. 2024 Nov 25:1-2. doi: 10.1017/ice.2024.
   PubMed        

   Int J Infect Dis

9. CHUN HM, Osawe S, Adams-Dabban S, Favaloro J, et al
   SARS-CoV-2 Serologic Surveillance Among People Living with HIV in Nigeria, April 2022-January 2023.
   Int J Infect Dis. 2024 Nov 21:107309. doi: 10.1016/j.ijid.2024.107309.
   PubMed         Abstract available
10. YANG X, Zhang J, Liu Z, Chen S, et al
    Real-world effectiveness of COVID-19 vaccine in people with HIV compared with a matched HIV-negative cohort: a test-negative design.
    Int J Infect Dis. 2024 Nov 22:107310. doi: 10.1016/j.ijid.2024.107310.
    PubMed         Abstract available
11. PETT SL
    Predictors of hospitalisation, death and incomplete/non-recovery from SARS-CoV-2 in an ambulatory global population.
    Int J Infect Dis. 2024 Nov 26:107285. doi: 10.1016/j.ijid.2024.107285.
    PubMed         Abstract available

    J Infect

12. JIA T, Wang F, Chen Y, Liao G, et al
    Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    J Infect. 2024 Nov 26:106362. doi: 10.1016/j.jinf.2024.106362.
    PubMed         Abstract available

    J Med Virol

13. SIDDIQUE AI, Sarmah N, Bali NK, Nausch N, et al
    Differential Gene Expression and Transcriptomics Reveal High M-Gene Expression in JN.1 and KP.1/2 Omicron Sub-Variants of SARS-CoV-2: Implications for Developing More Sensitive Diagnostic Tests.
    J Med Virol. 2024;96:e70074.
    PubMed         Abstract available
14. USHIJIMA H, Pham NTK, Nishimura S, Kobayashi M, et al
    Human Astrovirus Infection and Outbreaks in Japanese Children Before and After the Emergence of COVID-19 Pandemic.
    J Med Virol. 2024;96:e70078.
    PubMed         Abstract available
15. CHEN J, Zhang Y, Zhang B, Wang Z, et al
    In Vitro Characterization of Inhibition Function of Calcifediol to the Protease Activity of SARS-COV-2 PLpro.
    J Med Virol. 2024;96:e70085.
    PubMed         Abstract available
16. TIAN W, Han Z, Shi D, Wang H, et al
    Indeterminate Result of Interferon-gamma Release Assay-A Risk Factor of Mortality for COVID-19 and Non-COVID-19 Respiratory Infections.
    J Med Virol. 2024;96:e70058.
    PubMed         Abstract available
17. GRANINGER M, Endmayr V, Kuhner LM, Berger SM, et al
    Association Between NK Cell Genetic Variants and the Development of Long COVID Associated- and Prepandemic Small Fiber Neuropathy.
    J Med Virol. 2024;96:e70091.
    PubMed         Abstract available
18. WANG J, Ni S, Chen Q, Wang C, et al
    Discovery of a Novel Public Antibody Lineage Correlated With Inactivated SARS-CoV-2 Vaccine and the Resultant Neutralization Activity.
    J Med Virol. 2024;96:e70073.
    PubMed         Abstract available

    J Virol

19. KAKIZAKI M, Hashimoto R, Nagata N, Yamamoto T, et al
    The respective roles of TMPRSS2 and cathepsins for SARS-CoV-2 infection in human respiratory organoids.
    J Virol. 2024 Nov 27:e0185324. doi: 10.1128/jvi.01853.
    PubMed         Abstract available

    Lancet

20. FERRANTE M, D’Haens G, Jairath V, Danese S, et al
    Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study.
    Lancet. 2024 Nov 21:S0140-6736(24)01762-8. doi: 10.1016/S0140-6736(24)01762.
    PubMed         Abstract available
21. DWYER-LINDGREN L, Baumann MM, Li Z, Kelly YO, et al
    Ten Americas: a systematic analysis of life expectancy disparities in the USA.
    Lancet. 2024 Nov 19:S0140-6736(24)01495-8. doi: 10.1016/S0140-6736(24)01495.
    PubMed         Abstract available

    Lancet Infect Dis

22. GOSWAMI J, Cardona JF, Hsu DC, Simorellis AK, et al
    Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Lancet Infect Dis. 2024 Nov 25:S1473-3099(24)00589.
    PubMed         Abstract available
23. LIU J, Yu Y, Jian F, Yang S, et al
    Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.
    Lancet Infect Dis. 2024 Nov 22:S1473-3099(24)00738.
    PubMed        

    Science

24. LIBBY P
    Endothelial inflammation in COVID-19.
    Science. 2024;386:972-973.
    PubMed         Abstract available
25. COHEN J
    Children are left behind in Congo’s mpox vaccination drive.
    Science. 2024;386:954.
    PubMed         Abstract available

    Travel Med Infect Dis

26. KHAN AA, Balkhi BS, Alamri FA, Alsaleh GS, et al
    Vaccinations for Hajj: Enhancing health and global health security.
    Travel Med Infect Dis. 2024;63:102784.
    PubMed         Abstract available
27. WANG J, Ge L, Zhou K, Jiang Y, et al
    Effect of omicron infection on maternal and neonatal delivery outcomes: A retrospective cohort study.
    Travel Med Infect Dis. 2024;62:102759.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #vaccine

get air filters. Don't like masks? Can't wear respirators? Filter your air!

Push your local school(s) to fundraise for air filters.

https://medium.com/@carlvank/luchtreiniging-air-purification-hepa-5dd2c728ef8f

https://www.chemistryworld.com/features/can-we-clean-covid-from-the-air-around-us/4016017.article/

https://thetyee.ca/Analysis/2023/01/11/Revolution-Clean-Indoor-Air/

https://www.cdc.gov/mmwr/volumes/70/wr/pdfs/mm7027e1-H.pdf

https://onlinelibrary.wiley.com/doi/10.1111/ina.12968

https://pubs.rsc.org/en/content/articlelanding/2024/em/d4em00114a

https://pubs.aip.org/aip/pof/article/33/3/033321/1064105/Transmission-and-reduction-of-aerosols-in#_i33

https://www.bfmmagazine.co.uk/air-purifiers-for-schools-study-results-pave-the-way-for-long-term-corona-strategy

https://journals.asm.org/doi/10.1128/msphere.00086-22

https://www.tandfonline.com/doi/full/10.1080/02786826.2021.1877257

https://www.journalofhospitalinfection.com/article/S0195-6701(23)00078-6/pdf

https://academic.oup.com/cid/article/75/1/e97/6414657?guestAccessKey=248e14cc-d920-4782-99b7-634e47cdaa0e

https://www.cam.ac.uk/research/news/air-filter-significantly-reduces-presence-of-airborne-sars-cov-2-in-covid-19-wards

https://pmc.ncbi.nlm.nih.gov/articles/PMC8314194/

#covid #covid19 #CovidIsNotOver #LongHaulers #LongCovidKids #LongCovid #coronavirus #SarsCoV2 #SARS2 #air #Filter #AirPurifiers #IndoorAirQuality #CO2 #AirQuality

#Recombination across distant #coronavirid #species and #genera is a rare #event with distinct #genomic features

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01100-24?af=R

ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; family Coronaviridae, genus Betacoronavirus, subgenus Sarbecovirus) has caused millions of deaths, prompting a need for better understanding of coronavirid emergence and spillover to humans. As an evaluation of how some features of SARS-CoV-2, unique among sarbecoviruses, may have been acquired from related viruses, we conducted phylogenetic and recombination analyses to compare the frequency of recombination among coronavirids across vs within genera, subgenera, and species. Among known betacoronaviruses, we identified 199 (183 intraspecies, 16 interspecies, but no intersubgenera) recombination events. Phylogenetic analyses revealed that the ancestry of interspecies events was limited and less prone to affect 5′ regions of coronavirid genome open reading frame 1 (ORF1) than intraspecies events. On the contrary, interspecies events were significantly more prone to impact the 3′ end (ORF6–ORF8 and the nucleocapsid protein [N] ORF), suggesting the existence of region-specific constraints on recombination. This work substantiated that recombination among betacoronaviruses is limited by the genome similarity between their parental viruses. We conclude that SARS-CoV-2 likely acquired unique features through recombination with closely related circulating sarbecoviruses (most likely from the same species) that co-existed geographically.

____

#abstract #betacoronavirus #biology #coronavirus #evolution #genetics #health #research #sarbecovirus #sarsCov2 #science

#Coronavirus Disease Research #References (by AMEDEO, Nov. 16 ’24)

1. AYYALA-SOMAYAJULA D, Dodge JL, Leventhal AM, Terrault NA, et al
   Trends in Alcohol Use After the COVID-19 Pandemic: A National Cross-Sectional Study.
   Ann Intern Med. 2024 Nov 12. doi: 10.7326/ANNALS-24-02157.
   PubMed        

   Antiviral Res

2. SAMA B, Selisko B, Falcou C, Fattorini V, et al
   The effects of Remdesivir’s functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase.
   Antiviral Res. 2024 Nov 5:106034. doi: 10.1016/j.antiviral.2024.106034.
   PubMed         Abstract available

   BMJ

3. GREENHALGH T, Misak C, Payne R, Swann N, et al
   Patient involvement in developing clinical guidelines.
   BMJ. 2024;387:q2433.
   PubMed        

   Br J Anaesth

4. ANGELOPOULOS N, Staines J, Chamberlin M, Bates S, et al
   A narrative review of personal protective equipment gowns: lessons from COVID-19.
   Br J Anaesth. 2024 Nov 7:S0007-0912(24)00567-1. doi: 10.1016/j.bja.2024.
   PubMed         Abstract available

   Clin Infect Dis

5. GRANT R, de Kraker MEA, Buetti N, Jackson H, et al
   In-hospital outcomes of healthcare-associated COVID-19 (Omicron) versus healthcare-associated influenza: a retrospective, nationwide cohort study in Switzerland.
   Clin Infect Dis. 2024 Nov 13:ciae558. doi: 10.1093.
   PubMed         Abstract available
6. HAMMOND J, Leister-Tebbe H, Gardner A, Abreu P, et al
   Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-Risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A phase 3 randomized trial.
   Clin Infect Dis. 2024 Nov 11:ciae551. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

7. CREPPAGE KE, Gallaway MS, Russell DA, Early JM, et al
   Global Emerging Infections Surveillance Program Contributions to Pandemic Preparedness and Response.
   Emerg Infect Dis. 2024;30:9-12.
   PubMed         Abstract available
8. MORTON LC, Rahman N, Bishop-Lilly KA
   Next-Generation Sequencing and Bioinformatics Consortium Approach to Genomic Surveillance.
   Emerg Infect Dis. 2024;30:13-18.
   PubMed         Abstract available
9. MUEHLEMAN D, Gruner B, Hogan V, Fanning P, et al
   Using SARS-CoV-2 Sequencing Data to Identify Reinfection Cases in the Global Emerging Infections Surveillance Program, United States.
   Emerg Infect Dis. 2024;30:53-61.
   PubMed         Abstract available
10. TINOCO YO, Osman TS, Ampuero JS, Gazo M, et al
    Respiratory Disease Surveillance in the Middle East and Latin America during the COVID-19 Pandemic, 2020-2022.
    Emerg Infect Dis. 2024;30:26-32.
    PubMed         Abstract available
11. ODUNDO EA, Kipkirui EC, Koech MC, Kirui MC, et al
    Azithromycin Resistance Patterns in Escherichia coli and Shigella before and after COVID-19, Kenya.
    Emerg Infect Dis. 2024;30:86-93.
    PubMed         Abstract available

    Int J Infect Dis

12. GRIFFITHS M, Hatabah D, Sullivan P, Mantus G, et al
    Corrigendum to “Incidence of SARS-CoV-2 seropositivity in pediatric healthcare workers prior to widespread vaccination: A 5-month longitudinal cohort study” [Internation Journal of Infectious Diseases, volume 144 (2024) 107064].
    Int J Infect Dis. 2024;149:107278.
    PubMed        
13. LASTRUCCI V, Pacifici M, Puglia M, Alderotti G, et al
    Erratum to ‘Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study’.
    Int J Infect Dis. 2024;149:107286.
    PubMed        

    Intensive Care Med

14. KESECIOGLU J, Rusinova K, Alampi D, Arabi YM, et al
    European Society of Intensive Care Medicine guidelines on end of life and palliative care in the intensive care unit.
    Intensive Care Med. 2024 Oct 3. doi: 10.1007/s00134-024-07579.
    PubMed         Abstract available
15. OLMOS M, Esperatti M, Fuentes N, Miranda Tirado A, et al
    Early physiologic changes after awake prone positioning predict clinical outcomes in patients with acute hypoxemic respiratory failure.
    Intensive Care Med. 2024 Nov 14. doi: 10.1007/s00134-024-07690.
    PubMed         Abstract available

    J Infect

16. DULFER EA, Fohse K, Taks EJM, Moorlag SJCFM, et al
    The effect of BCG vaccination in the elderly on infectious and non-infectious immune-mediated diseases.
    J Infect. 2024;89:106344.
    PubMed         Abstract available
17. HAN B, Du C, Deng M, Tang R, et al
    Real-world effectiveness and safety of simnotrelvir/ritonavir for COVID-19: A nationwide, multicenter, prospective, observational cohort study in China.
    J Infect. 2024 Nov 7:106339. doi: 10.1016/j.jinf.2024.106339.
    PubMed         Abstract available
18. FOONG KS
    Corrigendum to “The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19” [J Infe
    J Infect. 2024;89:106343.
    PubMed        

    J Med Virol

19. USTIUZHANINA MO, Boyko AA, Vavilova JD, Siniavin AE, et al
    The Antigen-Specific Response of NK Cells to SARS-CoV-2 Correlates With KIR2DS4 Expression.
    J Med Virol. 2024;96:e70057.
    PubMed         Abstract available
20. ZHANG C, Wang M, Sun S, Yi M, et al
    Impact of COVID-19 on the Prevalence and Drug Resistance of Bacteria Isolated From Bacterial Meningitis Cerebrospinal Fluid in Shandong Province: A Multicenter Retrospective Study.
    J Med Virol. 2024;96:e70063.
    PubMed         Abstract available
21. ESPI M, Charmetant X, Benotmane I, Lefsihane K, et al
    Memory B Cells Provide Long-Term Protection to Vaccinated Kidney Transplant Recipients Against SARS-CoV-2 Variants.
    J Med Virol. 2024;96:e70037.
    PubMed         Abstract available
22. FACCO JV, Addas-Carvalho M, Duarte ADSS, Zangirolami AB, et al
    HLA-B*15 Is Associated With SARS-CoV-2 Infection in a Brazilian Population.
    J Med Virol. 2024;96:e70028.
    PubMed         Abstract available
23. WANG N, Lin Q, Fan H, Wang Y, et al
    BIC/FTC/TAF Benefits People Living With HIV After Omicron Breakthrough Infection in Shortening Duration of Symptoms, Enhancing Specific Immune Response and Increasing Total CD4 Cells.
    J Med Virol. 2024;96:e70036.
    PubMed         Abstract available
24. YE C, Tian Y, Huo D, Zhang T, et al
    Changes in Epidemics of Respiratory Viral Infections Resulted From the COVID-19 Pandemic in Shanghai.
    J Med Virol. 2024;96:e70034.
    PubMed         Abstract available

    J Virol

25. CHEN Y, Ou X, Li P, Zan F, et al
    Identification of the critical residues of TMPRSS2 for entry and host range of human coronavirus HKU1.
    J Virol. 2024 Nov 11:e0158724. doi: 10.1128/jvi.01587.
    PubMed         Abstract available
26. STEIGMANN JC, Zhou X, Suttenberg LN, Salman I, et al
    Effects of immunoproteasome inhibition on acute respiratory infection with murine hepatitis virus strain 1.
    J Virol. 2024 Nov 7:e0123824. doi: 10.1128/jvi.01238.
    PubMed         Abstract available

    JAMA

27. ANDERER S
    FDA Authorizes First At-Home COVID-19 and Flu Combo Test.
    JAMA. 2024 Nov 8. doi: 10.1001/jama.2024.22561.
    PubMed        

    Lancet

28. DWYER-LINDGREN L, Kendrick P, Baumann MM, Li Z, et al
    Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008-21: an analysis using the Human Development Index.
    Lancet. 2024 Nov 6:S0140-6736(24)01757-4. doi: 10.1016/S0140-6736(24)01757.
    PubMed         Abstract available
29. ALWAN NA, Al-Aly Z
    Learning from long COVID: conceptualising action to tackle infection-associated non-communicable diseases.
    Lancet. 2024 Nov 6:S0140-6736(24)02256-6. doi: 10.1016/S0140-6736(24)02256.
    PubMed        
30. Global, regional, and national stillbirths at 20 weeks’ gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021.
    Lancet. 2024 Nov 4:S0140-6736(24)01925-1. doi: 10.1016/S0140-6736(24)01925.
    PubMed         Abstract available

    Lancet Infect Dis

31. ARORA P, Happle C, Kempf A, Nehlmeier I, et al
    Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
    Lancet Infect Dis. 2024 Nov 7:S1473-3099(24)00688.
    PubMed        
32. KAKU Y, Okumura K, Kawakubo S, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 XEC variant.
    Lancet Infect Dis. 2024 Nov 6:S1473-3099(24)00731.
    PubMed        

    MMWR Morb Mortal Wkly Rep

33. LEFFERTS B, Bressler S, Keck JW, Desnoyers C, et al
    Nirsevimab Effectiveness Against Medically Attended Respiratory Syncytial Virus Illness and Hospitalization Among Alaska Native Children – Yukon-Kuskokwim Delta Region, Alaska, October 2023-June 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:1015-1021.
    PubMed         Abstract available
34. MINTA AA, Ferrari M, Antoni S, Lambert B, et al
    Progress Toward Measles Elimination – Worldwide, 2000-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:1036-1042.
    PubMed         Abstract available

    N Engl J Med

35. SCHMIDT P, Li Y, Popejoy M
    Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19.
    N Engl J Med. 2024;391:1860-1862.
    PubMed        
36. WANG Q, Guo Y, Ho J, Ho DD, et al
    Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages.
    N Engl J Med. 2024;391:1863-1864.
    PubMed        
37. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed         Abstract available

    Nature

38. JIAN F, Wang J, Yisimayi A, Song W, et al
    Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1.
    Nature. 2024 Nov 7. doi: 10.1038/s41586-024-08315.
    PubMed         Abstract available
39. SOLIMAN A
    US trust in scientists plunged during the pandemic – but it’s starting to recover.
    Nature. 2024 Nov 14. doi: 10.1038/d41586-024-03723.
    PubMed        

    Science

40. CHEN Z, Tsui JL, Gutierrez B, Busch Moreno S, et al
    COVID-19 pandemic interventions reshaped the global dispersal of seasonal influenza viruses.
    Science. 2024;386:eadq3003.
    PubMed         Abstract available
41. ROHANI P, Bahl J
    Collateral effects of pandemic control.
    Science. 2024;386:620-621.
    PubMed         Abstract available
42. VOGEL G
    ‘America first’ could affect health worldwide.
    Science. 2024;386:715.
    PubMed         Abstract available

#abstract #betacoronavirus #covid #COVID19 #health #news #research #sarbecovirus #sarsCov2

Source: npj Vaccines, https://www.nature.com/articles/s41541-024-01016-6

Abstract
We report SARS-CoV-2 KP.1, KP.1.1, KP.2 and KP.3 neutralizing antibody titers. They displayed increased immune evasion compared to JN.1, especially KP.1 and KP.3, for participants who experienced BF.7/BA.5.2 breakthrough infection or received bivalent (delta/BA.5) vaccine boosting. Second XBB sub-variants breakthrough infection enhanced the neutralization responses. HK.3-JN.1 RBD-heterodimer induced balanced and potent neutralizing responses against recently-circulating SARS-CoV-2 sub-variants in mice, supporting to replace the COVID-19 antigen containing JN.1 or its sub-variants.

_____

https://etidioh.wordpress.com/2024/11/11/neutralization-of-sars-cov-2-kp1-kp11-kp2-and-kp3-by-human-and-murine-sera/

#abstract #betacoronavirus #COVID19 #research #sarbecovirus #sarsCov2 #vaccines

1. SELINGER S
   Patients surviving COVID-19 had lower risk for long COVID in the Omicron vs. earlier eras.
   Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02441.
   PubMed         Abstract available

   BMJ

2. BARRETT A
   Covid-19: Australian inquiry calls for establishment of a national centre for disease control and action to tackle inequities.
   BMJ. 2024;387:q2420.
   PubMed        

   Clin Infect Dis

3. MORTEZAVI M, Sloan A, Singh RSP, Chen LF, et al
   Virologic Response and Safety of Ibuzatrelvir, a Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.
   Clin Infect Dis. 2024 Nov 2:ciae529. doi: 10.1093.
   PubMed         Abstract available

   Int J Infect Dis

4. NAVEED Z, Li J, Wilton J, Naus M, et al
   Healthcare utilization among COVID-19 mRNA vaccine-associated myocarditis cases: a matched retrospective cohort study.
   Int J Infect Dis. 2024 Nov 1:107287. doi: 10.1016/j.ijid.2024.107287.
   PubMed         Abstract available
5. EPSTEIN-SHUMAN A, Hunt JH, Caturegli P, Winguth P, et al
   Autoantibodies Directed Against Interferon Alpha, Nuclear Antigens, Cardiolipin, and Beta 2 Glycoprotein 1 Are Not Induced By SARS-CoV-2 or Associated with Long COVID.
   Int J Infect Dis. 2024 Nov 1:107289. doi: 10.1016/j.ijid.2024.107289.
   PubMed         Abstract available

   Intensive Care Med

6. WANG Y, Hao S, Song J, Zhong M, et al
   Reflections on awake prone positioning in COVID-19: considerations on body inclination, respiratory support, and patient variability.
   Intensive Care Med. 2024 Nov 4. doi: 10.1007/s00134-024-07710.
   PubMed        

   J Infect

7. WANG H, Zhou Y, Chu L, Chen K, et al
   Guardian-driven influenza vaccination intentions for children post-COVID-19 in the 2024-2025 season: The positive spillover effects.
   J Infect. 2024;89:106333.
   PubMed        
8. HO A, McInnes N, Blunsum A, Quinn J, et al
   Near real-time severe acute respiratory illness surveillance characterising influenza and COVID-19 epidemiology in hospitalised adults, 2021-22.
   J Infect. 2024;89:106338.
   PubMed         Abstract available

   J Virol

9. CHEN D, Zhang W, Xiao B, Xu B, et al
   Effect of wild-type vaccine doses on BA.5 hybrid immunity, disease severity, and XBB reinfection risk.
   J Virol. 2024 Nov 5:e0128524. doi: 10.1128/jvi.01285.
   PubMed         Abstract available
10. STEIN SC, Hansen G, Ssebyatika G, Stroh LJ, et al
    A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation.
    J Virol. 2024 Nov 4:e0122324. doi: 10.1128/jvi.01223.
    PubMed         Abstract available
11. PARRY RH, Lytras S, Petrone ME, Wille M, et al
    No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota.
    J Virol. 2024 Nov 4:e0146824. doi: 10.1128/jvi.01468.
    PubMed         Abstract available

    Life Sci

12. MARANGI M, Boughattas S, Benslimane F
    Gut microbiome profile to the level species in diarrheic protozoan-carrier patients in Italy.
    Life Sci. 2024 Oct 25:123182. doi: 10.1016/j.lfs.2024.123182.
    PubMed         Abstract available
13. ASHRAF MS, Tuli K, Moiz S, Sharma SK, et al
    AMP kinase: A promising therapeutic drug target for post-COVID-19 complications.
    Life Sci. 2024;359:123202.
    PubMed         Abstract available

    Zhonghua Jie He He Hu Xi Za Zhi

14. LIANG SF, Li WM, Liu D
    [Progress and challenges in clinical diagnosis and treatment of co-existent lung cancer and pulmonary tuberculosis].
    Zhonghua Jie He He Hu Xi Za Zhi. 2024;47:1035-1041.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/10/coronavirus-disease-research-references-by-amedeo-nov-10-24/

#betacoronavirus #cancer #coronavirus #covid #COVID19 #health #mentalHealth #research #sarbecovirus #sarsCov2

1. NAKASHIMA M, Nobori H, Kuroda T, Shimba A, et al
   Oral 3CL protease inhibitor ensitrelvir suppressed SARS-CoV-2 shedding and infection in a hamster aerosol transmission model.
   Antiviral Res. 2024 Oct 28:106026. doi: 10.1016/j.antiviral.2024.106026.
   PubMed         Abstract available

   BMJ

2. DOWNAR J, Close E, Young JE, White BP, et al
   Assisted dying: balancing safety with access.
   BMJ. 2024;387:q2382.
   PubMed        

   Clin Infect Dis

3. BHIMRAJ A, Falck-Ytter Y, Kim AY, Li JZ, et al
   2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Management of COVID-19: Anti-SARS-CoV-2 Neutralizing Antibody Pemivibart for Pre-exposure Prophylaxis.
   Clin Infect Dis. 2024 Oct 29:ciae435. doi: 10.1093.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

4. QADDOURA A, McQuiston M, Tyrrell G, Croxen M, et al
   Analysis of invasive group A streptococcal puerperal sepsis in Calgary, Alberta: clinical consequences and policy implications.
   Infect Control Hosp Epidemiol. 2024;45:1-4.
   PubMed         Abstract available

   J Med Virol

5. SONG K, Hasan A, Hao W, Wu Y, et al
   Stimulator of interferon genes (STING) inhibits coronavirus infection by disrupting viral replication organelles.
   J Med Virol. 2024;96:e70020.
   PubMed         Abstract available
6. YILDIZ Y, Yasar E, Ozturk E, Karakan MS, et al
   Heterologous Versus Homologous COVID-19 Boosters: Immune Response Outcomes in Renal Transplant Recipients.
   J Med Virol. 2024;96:e70030.
   PubMed         Abstract available

   J Virol

7. LIU X, Zhang M, Yin L, Kang L, et al
   PEDV evades MHC-I-related immunity through nsp1-mediated NLRC5 translation inhibition.
   J Virol. 2024 Oct 31:e0142124. doi: 10.1128/jvi.01421.
   PubMed         Abstract available
8. SHI L, Duan Y, Cao L, Zhang Y, et al
   PF-00835231 broadly inhibits swine Alpha-coronavirus, including emerging SADS-CoV.
   J Virol. 2024 Oct 31:e0130324. doi: 10.1128/jvi.01303.
   PubMed         Abstract available
9. HOFFMANN M, Kleine-Weber H, Graichen L, Nehlmeier I, et al
   Acquisition of a multibasic cleavage site does not increase MERS-CoV entry into Calu-3 human lung cells.
   J Virol. 2024 Oct 29:e0130524. doi: 10.1128/jvi.01305.
   PubMed         Abstract available

   JAMA

10. TADROUS M, Callaway Kim K, Hernandez I, Rothenberger SD, et al
    Differences in Drug Shortages in the US and Canada.
    JAMA. 2024 Oct 31. doi: 10.1001/jama.2024.17688.
    PubMed         Abstract available

    Lancet Infect Dis

11. PASCAL G
    COVID-19 in South Asia.
    Lancet Infect Dis. 2024 Oct 22:S1473-3099(24)00723.
    PubMed        
12. OKADA Y, Kumagai Y, Okura I, Otsuki M, et al
    Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
    Lancet Infect Dis. 2024 Oct 23:S1473-3099(24)00565.
    PubMed         Abstract available

    Life Sci

13. YU LC
    Gastrointestinal pathophysiology in long COVID: Exploring roles of microbiota dysbiosis and serotonin dysregulation in post-infectious bowel symptoms.
    Life Sci. 2024;358:123153.
    PubMed         Abstract available
14. WANG N, Fan H, Wang Y, Shu C, et al
    The hybrid immunity defined by weaker immune imprinting of people living with HIV has a stronger neutralizing response against Omicron variants. A suggested explanation for fewer symptoms in people living with HIV after SARS-CoV-2 variants breakthroug
    Life Sci. 2024 Oct 29:123197. doi: 10.1016/j.lfs.2024.123197.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

15. BELL J, Meng L, Barbre K, Wong E, et al
    Influenza and COVID-19 Vaccination Coverage Among Health Care Personnel – National Healthcare Safety Network, United States, 2023-24 Respiratory Virus Season.
    MMWR Morb Mortal Wkly Rep. 2024;73:966-972.
    PubMed         Abstract available
16. JONES CE, Danovaro-Holliday MC, Mwinnyaa G, Gacic-Dobo M, et al
    Routine Vaccination Coverage – Worldwide, 2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:978-984.
    PubMed         Abstract available

    N Engl J Med

17. LITWINSKA-KMIECIK A, Mrowczynski K
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1658-1659.
    PubMed        
18. YANG C, Tebbutt SJ
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1659.
    PubMed        
19. XIE Y, Al-Aly Z
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras. Reply.
    N Engl J Med. 2024;391:1659-1660.
    PubMed        

    Nature

20. LIU P, Huang ML, Guo H, McCallum M, et al
    Design of customized coronavirus receptors.
    Nature. 2024 Oct 30. doi: 10.1038/s41586-024-08121.
    PubMed         Abstract available

    Science

21. LONG K
    Keeping outbreaks at bayCrisis Averted: The Hidden Science of Fighting Outbreaks Caitlin Rivers Viking, 2024. 320 pp.
    Science. 2024;386:499.
    PubMed         Abstract available
22. KUPFERSCHMIDT K
    You won’t believe this.
    Science. 2024;386:483-485.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/11/03/coronavirus-disease-research-references-by-amedeo-nov-3-24/

#betacoronavirus #coronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #science

Source: Journal of Virology, https://journals.asm.org/doi/10.1128/jvi.01305-24

ABSTRACT
Human-to-human transmission of the highly pathogenic Middle East respiratory syndrome coronavirus (MERS-CoV) is currently inefficient. However, there is concern that the virus might mutate and thereby increase its transmissibility and thus pandemic potential. The pandemic SARS-CoV-2 depends on a highly cleavable furin motif at the S1/S2 site of the viral spike (S) protein for efficient lung cell entry, transmission, and pathogenicity. Here, by employing pseudotyped particles, we investigated whether augmented cleavage at the S1/S2 site also increases MERS-CoV entry into Calu-3 human lung cells. We report that polymorphism T746K at the S1/S2 cleavage site or optimization of the furin motif increases S protein cleavage but not lung cell entry. These findings suggest that, unlike what has been reported for SARS-CoV-2, a highly cleavable S1/S2 site might not augment MERS-CoV infectivity for human lung cells.

____

https://etidioh.wordpress.com/2024/10/29/acquisition-of-a-multibasic-cleavage-site-does-not-increase-mers-cov-entry-into-calu-3-human-lung-cells/

#abstract #betacoronavirus #covid #COVID19 #health #merbecovirus #mersCov #research #sarbecovirus #sarsCov2 #science #vaccine

1. KURITZKES DR
   Remdesivir for Patients Hospitalized with COVID-19: Evidence of Effectiveness from Cohort Studies in the Omicron Era.
   Clin Infect Dis. 2024 Oct 24:ciae515. doi: 10.1093.
   PubMed        
2. WHITE EB, Grant L, Mak J, Olsho L, et al
   Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022-2023: A Prospective Cohort Study.
   Clin Infect Dis. 2024 Oct 24:ciae491. doi: 10.1093.
   PubMed         Abstract available
3. KALIL AC, Chandak A, Moore LSP, Ahuja N, et al
   Public Health Benefits of Applying Evidence-Based Best Practices in Managing Patients Hospitalized for COVID-19.
   Clin Infect Dis. 2024 Oct 25:ciae517. doi: 10.1093.
   PubMed         Abstract available

   Emerg Infect Dis

4. BRATCHER A, Kao SY, Chun K, Petropoulos CJ, et al
   Quantitative SARS-CoV-2 Spike Receptor-Binding Domain and Neutralizing Antibody Titers in Previously Infected Persons, United States, January 2021-February 2022.
   Emerg Infect Dis. 2024;30:2352-2361.
   PubMed         Abstract available
5. TAKAYAMA Y, Shimakawa Y, Matsuyama R, Chowell G, et al
   SARS-CoV-2 Infection in School Settings, Okinawa Prefecture, Japan, 2021-2022.
   Emerg Infect Dis. 2024;30:2343-2351.
   PubMed         Abstract available
6. DING K, Naqvi OH, Seeberger RJ, Bratzler DW, et al
   Spatiotemporal Ecologic Analysis of COVID-19 Vaccination Coverage and Outcomes, Oklahoma, USA, February 2020-December 2021.
   Emerg Infect Dis. 2024;30:2333-2342.
   PubMed         Abstract available
7. BURCKHARDT I, Burckhardt F
   Epidemiology of Streptococcus pyogenes Disease before, during, and after COVID-19 Pandemic, Germany, 2005-2023.
   Emerg Infect Dis. 2024;30:2435-2438.
   PubMed         Abstract available

   Infect Control Hosp Epidemiol

8. YAN J, McClure T, Aslam A, Bubb T, et al
   Impact of universal masking in reducing the risk of nosocomial respiratory viruses among people with cancer.
   Infect Control Hosp Epidemiol. 2024 Oct 25:1-5. doi: 10.1017/ice.2024.
   PubMed         Abstract available
9. BRAILITA DM, Soma M, Martinez R, Tyner L, et al
   The impact of statewide educational webinars on infection prevention and control knowledge and policy updates in acute and long-term care facilities during the COVID-19 pandemic: the Nebraska experience.
   Infect Control Hosp Epidemiol. 2024 Oct 23:1-4. doi: 10.1017/ice.2024.
   PubMed         Abstract available
10. SCHRANK GM, O’Hara LM, Pineles L, Popescu S, et al
    A survey of healthcare workers on the acceptance and value of personal protective equipment for patient care.
    Infect Control Hosp Epidemiol. 2024 Oct 23:1-5. doi: 10.1017/ice.2024.
    PubMed         Abstract available
11. IIJIMA K, Osako H, Iwata K
    Comparing the effectiveness of universal admission testing and risk-based testing at emergency admission for preventing nosocomial COVID-19: a multicenter retrospective cohort study in Japan.
    Infect Control Hosp Epidemiol. 2024 Oct 22:1-9. doi: 10.1017/ice.2024.
    PubMed         Abstract available
12. DE-LA-ROSA-MARTINEZ D, Vilar-Compte D, Martinez-Rivera N, Ochoa-Hein E, et al
    Multicenter study on Clostridioides difficile infections in Mexico: exploring the landscape.
    Infect Control Hosp Epidemiol. 2024 Oct 21:1-8. doi: 10.1017/ice.2024.
    PubMed         Abstract available
13. RAY MJ, Furuno JP, Strnad LC, Lofgren ET, et al
    Examining the impact of the COVID-19 pandemic on hospital-associated Clostridioides difficile infection.
    Infect Control Hosp Epidemiol. 2024 Oct 21:1-7. doi: 10.1017/ice.2024.
    PubMed         Abstract available

    Int J Infect Dis

14. AZHAR EI, Velavan TP, Rungsung I, Traore T, et al
    Corrigendum to “Middle East respiratory syndrome coronavirus-a 10-year (2012-2022) global analysis of human and camel infections, genomic sequences, lineages, and geographical origins” [International Journal of Infectious Diseases (2023), volume 131,
    Int J Infect Dis. 2024;149:107261.
    PubMed        

    J Virol

15. SONG X, Li Y, Wang C, Zhao Y, et al
    Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV heterologous strains with low cross-protection.
    J Virol. 2024 Sep 10:e0130924. doi: 10.1128/jvi.01309.
    PubMed         Abstract available
16. CAILLAVA AJ, Alfonso V, Tejerina Cibello M, Demaria MA, et al
    A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.
    J Virol. 2024 Oct 23:e0101724. doi: 10.1128/jvi.01017.
    PubMed         Abstract available
17. ZHANG C, Jiang Q, Liu Z, Li N, et al
    SARS-CoV-2 NSP6 reduces autophagosome size and affects viral replication via sigma-1 receptor.
    J Virol. 2024 Oct 24:e0075424. doi: 10.1128/jvi.00754.
    PubMed         Abstract available

    JAMA

18. ANDERER S
    HHS Will Provide Free US-Made COVID-19 Tests to Households.
    JAMA. 2024 Oct 25. doi: 10.1001/jama.2024.21819.
    PubMed        

    Life Sci

19. DOS SANTOS L, Favaroni Mendes Salgado Ribeiro LA, Febba Gomes AC, Azinheira Nobrega Cruz N, et al
    ACE and ACE2 activities and polymorphisms assessment: A populational study from Ipaussu (SP, Brazil) during the COVID-19 pandemic.
    Life Sci. 2024;358:123157.
    PubMed         Abstract available

    MMWR Morb Mortal Wkly Rep

20. MA KC, Castro J, Lambrou AS, Rose EB, et al
    Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages – United States, May 2023-September 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:938-945.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/10/27/coronavirus-disease-research-references-by-amedeo-october-27-24/

#abstract #betacoronavirus #covid #COVID19 #exercise #health #nutrition #prevention #research #sarbecovirus #sarsCov2

Source: Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00574-7/fulltext?rss=yes

Summary
Background
Existing studies on SARS-CoV-2 infection have mainly focused on severe clinical outcomes; understanding of the clinical severity profile of general community infections is poor. We aimed to assess and compare the clinical profiles of infections with SARS-CoV-2 omicron (B.1.1.529) subvariants in a representative community cohort in Hong Kong during periods of BA.2, BA.4/5, and XBB dominance.

Methods
In this prospective cohort study in Hong Kong, a representative community cohort of individuals aged at least 5 years were recruited by random-digit dialling and underwent weekly rapid antigen testing for SARS-CoV-2, irrespective of symptoms, during three periods from March 1, 2022, to Oct 31, 2023, in which the BA.2, BA.4/5, or XBB subvariants were dominant. We analysed the likelihood of symptoms, as well as the patterns, severity, and duration of symptoms and their associations with participant demographics and vaccination and infection histories.

Findings
1126 (11·0%) of 10 279 participants in the BA.2 period, 830 (6·6%) of 12 588 in the BA.4/5 period, and 633 (11·1%) of 5690 during the XBB period tested positive for SARS-CoV-2 infection on rapid antigen tests. Community infections were generally mild, with asymptomatic infections comprising 22·0–25·0% of infections. No hospitalisations or deaths occurred as a direct result of SARS-CoV-2 infection during the study period. Compared with children aged 5–17 years, a higher likelihood of being symptomatic on infection was found for adults aged 18–59 years during the period of BA.2 dominance and adults aged 60 years or older during XBB dominance. Most (>90·0%) participants with symptomatic infections reported respiratory and systemic symptoms. Up-to-date vaccination with a regimen containing the BNT162b2 vaccine, compared with those without an up-to-date vaccine, was associated with a reduced likelihood of symptoms on infection during the period of BA.2 dominance and of severe symptoms causing substantial disturbance to daily life (grade 3 symptoms) during periods of BA.2 and BA.4/5 dominance, whereas no association was observed during the period of XBB dominance. Previous SARS-CoV-2 infection was associated with a reduced likelihood of symptoms on infection during BA.4/5 and XBB dominance and of severe symptoms during XBB dominance. Reports of severe symptoms increased over the three periods, from 236 (27·7%) of 852 symptomatic participants during BA.2 dominance to 176 (37·1%) of 475 during XBB dominance. The duration of symptoms was longest in the BA.2 period (median 10·0 days [95% CI 9·0–10·0]) and similar in the other two periods (8·0 [8·0–9·0] during BA.4/5 dominance and 8·0 [8·0–9·0] during XBB dominance). A symptom duration of 60 days or longer was reported only during the period of BA.2 dominance, in six (0·7%) of 824 infections.

Interpretation
SARS-CoV-2 infections were generally mild, but not increasingly so, along the evolution of omicron subvariants in this highly vaccinated population. About a third of participants with symptomatic infections reported that the symptoms severely affected daily life even if they were not admitted to hospital, resulting in morbidity, absence from work or school due to illness, productivity loss, and increased medicoeconomic burden. A gradual reduction in the association of vaccines and increase in the association of previous infection with the symptom profile, possibly reflecting the effects of immune escape and waning, were observed over the study period.

____

https://etidioh.wordpress.com/2024/10/15/clinical-profile-analysis-of-sars-cov-2-community-infections-during-periods-with-omicron-ba2-ba4-5-and-xbb-dominance-in-hk-a-prospective-cohort-study/

#abstract #betacoronavirus #coronavirus #covid #COVID19 #health #HKPRCSAR #omicron #research #sarbecovirus #sarsCov2 #vaccine

Source: Nature Communications, https://www.nature.com/articles/s41467-024-52808-2

Abstract
Since 2019, SARS-CoV-2 has undergone mutations, resulting in pandemic and epidemic waves. The SARS-CoV-2 spike protein, crucial for cellular entry, binds to the ACE2 receptor exclusively when its receptor-binding domain (RBD) adopts the up-conformation. However, whether ACE2 also interacts with the RBD in the down-conformation to facilitate the conformational shift to RBD-up remains unclear. Herein, we present the structures of the BA.2.86 and the JN.1 spike proteins bound to ACE2. Notably, we successfully observed the ACE2-bound down-RBD, indicating an intermediate structure before the RBD-up conformation. The wider and mobile angle of RBDs in the up-state provides space for ACE2 to interact with the down-RBD, facilitating the transition to the RBD-up state. The K356T, but not N354-linked glycan, contributes to both of infectivity and neutralizing-antibody evasion in BA.2.86. These structural insights the spike-protein dynamics would help understand the mechanisms underlying SARS-CoV-2 infection and its neutralization.

____

https://etidioh.wordpress.com/2024/10/07/structural-basis-for-receptor-binding-domain-mobility-of-the-spike-in-sars-cov-2-ba286-and-jn1/

#abstract #betacoronavirus #covid #COVID19 #health #research #sarbecovirus #sarsCov2 #science

“Is vaccine-induced immunity better than immunity from infection?

Vaccine-induced immunity is better because it’s safer. When you get infected with COVID, symptoms from the infection wreak havoc on your body. Whether or not you’ve been infected or vaccinated previously, the COVID booster is going to strengthen your immune responses to high levels and do so in a safe way.

Can I still get COVID if I’m vaccinated?

People who are vaccinated can still get COVID, but it is much more likely they will experience mild symptoms. Vaccinated people are much less likely to experience severe illness or get so sick that they need to be hospitalized. Data continue to show that those who are hospitalized with COVID are largely people who have not received a COVID vaccine within the past 12 months.

Particularly for people at higher risk of severe COVID, vaccination is an essential tool for reducing COVID complications, hospitalization, and death.

Can you get the flu shot and the COVID vaccine at the same time?

Yes! In fact, studies have shown that people who decide to spread out their vaccines into separate appointments often don’t follow through with getting both. We’ve also seen that the immune response generated by each vaccine does not change based on whether they are administered at the same time or separately.

It’s important to remember that many of the same populations at high risk of experiencing severe illness from COVID are also at high risk of severe influenza. Especially for these vulnerable populations, it’s a good idea to time your vaccines together.”

https://publichealth.jhu.edu/2024/what-to-know-about-updated-covid-vaccines-for-2024-25

#influenza #flu #justAflu #virus #viral #pathogen #updated #fluJab #NEW #newJab #SARScov2 #covid19 #COVID_19 #covid #CovidIsNotOver #coronaIstNichtVorbei #coronavirus #herdImmunity #helpOthers #RandomActsOfKindness #selfcare #carers #ally #allies #Disabled

1. VAN DER HORST D, Carter-Timofte ME, Danneels A, Silva da Costa L, et al
   Large-scale deep learning identifies the antiviral potential of PKI-179 and MTI-31 against coronaviruses.
   Antiviral Res. 2024;231:106012.
   PubMed         Abstract available

   BMJ

2. IACOBUCCI G
   Covid inquiry hears harrowing evidence of effects on ICU staff.
   BMJ. 2024;386:q2125.
   PubMed        
3. NABAVI N
   Mix of relief and disappointment-striking a balance in the pay deal for resident doctors in England.
   BMJ. 2024;386:q2116.
   PubMed        
4. BOUM Y 2ND, Ndembi N
   Mpox needs a locally tailored global response.
   BMJ. 2024;386:q2094.
   PubMed        
5. DARLOW J
   Is the NHS “broken”? Staff haven’t given up, neither should our politicians.
   BMJ. 2024;386:q2130.
   PubMed        
6. DEMASI M
   Journal retracts Covaxin study after manufacturer sues for defamation.
   BMJ. 2024;386:q2119.
   PubMed        
7. Seven days in medicine: 18-24 September 2024.
   BMJ. 2024;386:q2087.
   PubMed        
8. TANNE JH
   Whooping cough: Fivefold rise in US cases spells return to pre-pandemic levels.
   BMJ. 2024;386:q2114.
   PubMed        
9. MAHASE E
   Politicians are failing to prepare for next pandemic, warns head of European health agency.
   BMJ. 2024;386:q2115.
   PubMed        
10. MAHASE E
    Covid inquiry: UKHSA chief is challenged on view that evidence for FFP3 masks is “weak”.
    BMJ. 2024;386:q2075.
    PubMed        

    Clin Infect Dis

11. TRAN KC, Asfar P, Cheng M, Demiselle J, et al
    Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial.
    Clin Infect Dis. 2024;79:615-625.
    PubMed         Abstract available
12. FONG Y, Dang L, Zhang B, Fintzi J, et al
    Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
    Clin Infect Dis. 2024 Sep 26:ciae465. doi: 10.1093.
    PubMed         Abstract available
13. Correction to: Changes in the Appropriateness of US Outpatient Antibiotic Prescribing After the COVID-19 Outbreak: An Interrupted Time series Analysis of 2017-2021 Data.
    Clin Infect Dis. 2024 Sep 25:ciae455. doi: 10.1093.
    PubMed        

    Emerg Infect Dis

14. CHARLES H, Thorley K, Turner C, Bennet KF, et al
    Mpox Epidemiology and Vaccine Effectiveness, England, 2023.
    Emerg Infect Dis. 2024;30:2145-2148.
    PubMed         Abstract available
15. WERNIKE K, Mehl C, Aebischer A, Ulrich L, et al
    SARS-CoV-2 and Other Coronaviruses in Rats, Berlin, Germany, 2023.
    Emerg Infect Dis. 2024;30:2205-2208.
    PubMed         Abstract available
16. LININGER N, Falender R, Cieslak P, Novak A, et al
    Correlation between Viral Wastewater Concentration and Respiratory Tests, Oregon, USA.
    Emerg Infect Dis. 2024;30:2194-2196.
    PubMed         Abstract available

    Infect Control Hosp Epidemiol

17. BRANCH-ELLIMAN W, Banach DB, Batshon LJ, Dumyati G, et al
    SHEA position statement on pandemic preparedness for policymakers: pandemic data collection, maintenance, and release.
    Infect Control Hosp Epidemiol. 2024;45:821-825.
    PubMed         Abstract available
18. HSU VP, Pergam SA, Shenoy ES, Banach DB, et al
    SHEA position statement on pandemic preparedness for policymakers: emerging infectious threats.
    Infect Control Hosp Epidemiol. 2024;45:818-820.
    PubMed        
19. DEWITT ME, Sampson MM, Kester S, MacNeill E, et al
    Racial disparities in central line-associated bloodstream infections: the impact of the COVID-19 pandemic.
    Infect Control Hosp Epidemiol. 2024 Sep 26:1-5. doi: 10.1017/ice.2024.
    PubMed         Abstract available

    Int J Infect Dis

20. LEE JA, Jang H, Ahn SM, Seong JE, et al
    Estimates of Vaccine Effectiveness of the Updated Monovalent XBB.1.5 COVID-19 Vaccine Against Symptomatic SARS-CoV-2 Infection, Hospitalization, and Receipt of Oxygen Therapy in South Korea – October 26 to December 31, 2023.
    Int J Infect Dis. 2024 Sep 20:107249. doi: 10.1016/j.ijid.2024.107249.
    PubMed         Abstract available
21. TAKAHASHI H, Morikawa M, Satake Y, Nagamatsu H, et al
    Diagnostic Utility of Pharyngeal Follicular Structures in COVID-19: A Large-scale Cross-Sectional Study.
    Int J Infect Dis. 2024 Sep 21:107244. doi: 10.1016/j.ijid.2024.107244.
    PubMed         Abstract available

    J Infect

22. MCLEOD C, Dymock, Flanagan KL, Plebanski M, et al
    The Platform Trial In COVID-19 Priming and BOOsting (PICOBOO): the immunogenicity, reactogenicity, and safety of different COVID-19 vaccinations administered as a second booster (fourth dose) in AZD1222 primed individuals aged 50-<70 years old.
    J Infect. 2024 Sep 26:106286. doi: 10.1016/j.jinf.2024.106286.
    PubMed         Abstract available
23. VEGA-PIRIS L, Carretero SG, Mayordomo JL, Zarzuelo MBR, et al
    Severity of Respiratory Syncytial Virus compared with SARS-CoV-2 and Influenza among hospitalised adults >/=65 years.
    J Infect. 2024 Sep 26:106292. doi: 10.1016/j.jinf.2024.106292.
    PubMed         Abstract available
24. CHEN X, Balliew J, Bauer CX, Deegan J, et al
    Revealing patterns of SARS-CoV-2 variant emergence and evolution using RBD amplicon sequencing of wastewater.
    J Infect. 2024 Sep 26:106284. doi: 10.1016/j.jinf.2024.106284.
    PubMed         Abstract available
25. RABDANO SO, Ruzanova EA, Vertyachikh AE, Teplykh VA, et al
    N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial.
    J Infect. 2024 Sep 26:106288. doi: 10.1016/j.jinf.2024.106288.
    PubMed         Abstract available
26. SABATE-ELABBADI A, Brolon L, Brun-Buisson C, Guillemot D, et al
    Trends in hospitalisations for lower respiratory infections after the COVID-19 pandemic in France.
    J Infect. 2024 Sep 26:106287. doi: 10.1016/j.jinf.2024.106287.
    PubMed         Abstract available

    J Med Virol

27. KUHN D, Heinen N, Sutter K, Herrmann ST, et al
    Divergent autoantibody and cytokine levels in COVID-19 sepsis patients influence survival.
    J Med Virol. 2024;96:e29935.
    PubMed         Abstract available
28. LOVELL JF, Miura K, Baik YO, Lee C, et al
    Interim safety and immunogenicity analysis of the EuCorVac-19 COVID-19 vaccine in a Phase 3 randomized, observer-blind, immunobridging trial in the Philippines.
    J Med Virol. 2024;96:e29927.
    PubMed         Abstract available
29. LI H, Yang Y, Tao R, Shang S, et al
    Analyzing infections caused by 11 respiratory pathogens in children: Pre- and post-COVID-19 pandemic trends in China.
    J Med Virol. 2024;96:e29929.
    PubMed         Abstract available
30. HORI M, Hayama-Terada M, Kitamura A, Hosozawa M, et al
    Risk factors for post-coronavirus disease condition in the Alpha-, Delta-, and Omicron-dominant waves among adults in Japan: A population-based matched case-control study.
    J Med Virol. 2024;96:e29928.
    PubMed         Abstract available

    J Virol

31. KANG JS, Zhou K, Wang H, Tang S, et al
    Architectural organization and in situ fusion protein structure of lymphocytic choriomeningitis virus.
    J Virol. 2024 Sep 27:e0064024. doi: 10.1128/jvi.00640.
    PubMed         Abstract available

    JAMA

32. ANDERER S
    Caseload Strain Contributed to 1 in 5 COVID-19 Deaths at US Hospitals.
    JAMA. 2024 Sep 27. doi: 10.1001/jama.2024.19687.
    PubMed        

    Lancet

33. IMANI-MUSIMWA P, Ververs M
    Mpox and breastmilk: for once, can we act in time?
    Lancet. 2024 Sep 13:S0140-6736(24)01881-6. doi: 10.1016/S0140-6736(24)01881.
    PubMed        
34. HORTON R
    Offline: Xenotransplantation-a new era beckons.
    Lancet. 2024;404:1181.
    PubMed        
35. ROMANELLO M, Costello A
    The Lancet Countdown on health and climate change: competing interests and optimism bias – Authors’ reply.
    Lancet. 2024;404:1197-1198.
    PubMed        
36. BRINK N, Chersich MF
    The Lancet Countdown on health and climate change: competing interests and optimism bias.
    Lancet. 2024;404:1196.
    PubMed        
37. BUTLER CD, Combs Bowles D, Hanigan IC, Harmer A, et al
    The Lancet Countdown on health and climate change: competing interests and optimism bias.
    Lancet. 2024;404:1196-1197.
    PubMed        
38. ROMANELLO M, Beggs PJ, Cai W, Gordon-Strachan G, et al
    The Lancet Countdown on health and climate change: representation matters – Authors’ reply.
    Lancet. 2024;404:1195-1196.
    PubMed        
39. STREET R, Wright CY
    The Lancet Countdown on health and climate change: representation matters.
    Lancet. 2024;404:1194.
    PubMed        

    Lancet Infect Dis

40. DAS M
    Understanding outbreak preparedness.
    Lancet Infect Dis. 2024;24:1079.
    PubMed        
41. OLBRICH L, Franckling-Smith Z, Larsson L, Sabi I, et al
    Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00494.
    PubMed         Abstract available
42. LAWSON M
    Globalisation and COVID-19.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00621.
    PubMed        
43. TERSTAPPEN J, Hak SF, Bhan A, Bogaert D, et al
    The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.
    Lancet Infect Dis. 2024 Sep 23:S1473-3099(24)00455.
    PubMed         Abstract available
44. FIGUEROA AL, Torres D, Reyes-Acuna C, Matherne P, et al
    Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial.
    Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00501.
    PubMed         Abstract available
45. WANG WX, Zhu FC
    COVID-19 immunisation strategies for adolescents.
    Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00563.
    PubMed        
46. HAPPLE C, Hoffmann M, Kempf A, Nehlmeier I, et al
    Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination.
    Lancet Infect Dis. 2024 Sep 25:S1473-3099(24)00603.
    PubMed        

    MMWR Morb Mortal Wkly Rep

47. HAVERS FP, Whitaker M, Chatwani B, Patton ME, et al
    COVID-19-Associated Hospitalizations and Maternal Vaccination Among Infants Aged <6 Months – COVID-NET, 12 States, October 2022-April 2024.
    MMWR Morb Mortal Wkly Rep. 2024;73:830-836.
    PubMed         Abstract available
48. HILL HA, Yankey D, Elam-Evans LD, Mu Y, et al
    Decline in Vaccination Coverage by Age 24 Months and Vaccination Inequities Among Children Born in 2020 and 2021 – National Immunization Survey-Child, United States, 2021-2023.
    MMWR Morb Mortal Wkly Rep. 2024;73:844-853.
    PubMed         Abstract available

    Nature

49. The youngest among us fight COVID-19 in their own way.
    Nature. 2024 Sep 24. doi: 10.1038/d41586-024-03091.
    PubMed   

https://etidioh.wordpress.com/2024/09/29/coronavirus-disease-research-references-amedeo-september-29-24/

#betacoronavirus #covid #COVID19 #health #pandemic #research #sarbecovirus #sarsCov2 #vaccine

«Die Zahl der Patienten mit COVID-19 ist in der Ukraine um das 13-fache gestiegen - Gesundheitsministerium»

https://ukraine-nachrichten.de/zahl-patienten-covid-19-ukraine-13-fache-gestiegen-gesundheitsministerium_21866?mtm_source=mastodon&mtm_medium=social&mtm_campaign=ma

#Ukraine #Coronavirus #Covid19 #Covid19Pandemie #Epidemien #Gesundheitsministerium #Kiew #Krankheiten #Kyjiw #Pandemie #SarsCov2

Molecular Trickery: How COVID-19 Silently Sabotages the Human Immune System

Julia Moióli, São Paulo Research Foundation

August 22, 2024

https://scitechdaily.com/molecular-trickery-how-covid-19-silently-sabotages-the-human-immune-system/

#SarsCoV2
#COVID19
#IDMastodon
@noyes

«Im Juli hat sich die Inzidenz des Coronavirus in der Ukraine versechsfacht»

https://ukraine-nachrichten.de/juli-sich-inzidenz-coronavirus-ukraine-versechsfacht_21675?mtm_source=mastodon&mtm_medium=social&mtm_campaign=ma

#Ukraine #Coronavirus #Covid19 #Covid19Pandemie #Epidemien #Krankheiten #Pandemie #SarsCov2 #Usa

Quartet-Nanocages könnten die Zukunft der #Impfstoffe sein. Diese #Nanocages verknüpfen vier verschiedene Teile des #Spike-Proteins von #Coronaviren und regen dadurch die Produktion breiter neutralisierender #Antikörper an. Besonders spannend: Selbst wenn das #Virus mutiert, bleibt die #Schutzwirkung bestehen. In Studien zeigten Tiere mit bestehender #SARSCoV2-Immunität nach #BoosterImpfungen eine verbesserte #Antikörperantwort.

#Science #Coronavirus #COVID19

https://www.nature.com/articles/s41565-024-01655-9

"Viral persistence and sustained immune activation are linked to Long Covid."

https://www.science.org/doi/10.1126/scitranslmed.adk3295

#LongCOVID #NotInYourHead #SARSCov2 #Virology #ChronicDisease #ViralInfection #ViralRNA #ImmuneCells #TCells #ViralPersistence

«Ukrainer mit abgelaufenen Pässen können in Ungarn eine Aufenthaltserlaubnis erhalten»

https://ukraine-nachrichten.de/ukrainer-abgelaufenen-p%C3%A4ssen-k%C3%B6nnen-ungarn-eine-aufenthaltserlaubnis-erhalten_20863?mtm_source=mastodon&mtm_medium=social&mtm_campaign=ma

#Ukraine #Aufenthaltsgenehmigung #Coronavirus #Covid19 #Covid19Pandemie #Epidemien #Krankheiten #Pandemie #Regierung #SarsCov2 #Staatsbürgerschaft #Ungarn

1. June 1 Highlight.
   Am J Respir Crit Care Med. 2024;209:xxxvii-xxxviii.
   PubMed        

   BMJ

2. REYNOLDS C, Naqvi H
   Better use of data can help to prevent future deaths.
   BMJ. 2024;385:q1181.
   PubMed        
3. LYNN E
   May top picks: politics, psychological safety, and creativity.
   BMJ. 2024;385:q1166.
   PubMed        
4. TAYLOR L
   Pandemic treaty: panel calls for “reset” to talks as negotiators miss deadline.
   BMJ. 2024;385:q1193.
   PubMed        
5. LIMB M
   Labour’s pledge to clear NHS waiting list within five years will be tough to achieve, say leaders.
   BMJ. 2024;385:q1186.
   PubMed        
6. KMIETOWICZ Z
   Junior doctors in England announce five day walkout ahead of general election.
   BMJ. 2024;385:q1183.
   PubMed        
7. MAHASE E
   GPs could threaten mass resignation over NHS contract.
   BMJ. 2024;385:q1182.
   PubMed        
8. WISE J
   Improving infection prevention could avoid 750 000 deaths a year, say experts.
   BMJ. 2024;385:q1163.
   PubMed        
9. DYER O
   Covid-19: South African disclosures reveal secretive world of nations’ vaccine contracts.
   BMJ. 2024;385:q1172.
   PubMed        

   Clin Infect Dis

10. WOLFE DN, Arangies E, David GL, Armstrong B, et al
    Development of Next-Generation COVID-19 Vaccines: BARDA Supported Phase 2b Study Designs.
    Clin Infect Dis. 2024 May 28:ciae286. doi: 10.1093.
    PubMed         Abstract available
11. HILL JA, Martens MJ, Young JH, Bhavsar K, et al
    SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study.
    Clin Infect Dis. 2024 May 27:ciae291. doi: 10.1093.
    PubMed         Abstract available

    Int J Infect Dis

12. REEKIE J, Stovring H, Nielsen H, Johansen IS, et al
    Development of antibody levels and subsequent decline in individuals with vaccine induced and hybrid immunity to SARS-CoV-2.
    Int J Infect Dis. 2024 May 25:107111. doi: 10.1016/j.ijid.2024.107111.
    PubMed         Abstract available

    Intensive Care Med

13. OUD L
    Long-term outcomes of critically ill patients with hematological malignancies: what is the impact of the coronavirus disease 2019 pandemic?
    Intensive Care Med. 2024 May 28. doi: 10.1007/s00134-024-07493.
    PubMed        

    J Med Virol

14. HAN Y, Ma Y, Wang Z, Feng F, et al
    TMPRSS13 promotes the cell entry of swine acute diarrhea syndrome coronavirus.
    J Med Virol. 2024;96:e29712.
    PubMed         Abstract available
15. BORGOGNA C, Ferrante D, Rosso G, Guglielmetti G, et al
    A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine.
    J Med Virol. 2024;96:e29710.
    PubMed         Abstract available
16. PAVIA G, Quirino A, Marascio N, Veneziano C, et al
    Persistence of SARS-CoV-2 infection and viral intra- and inter-host evolution in COVID-19 hospitalized patients.
    J Med Virol. 2024;96:e29708.
    PubMed         Abstract available
17. KOW CS, Ramachandram DS, Hasan SS, Thiruchelvam K, et al
    Antibiotics in COVID-19: Unveiling disturbing truths through critical scrutiny.
    J Med Virol. 2024;96:e29720.
    PubMed        
18. CHEN IW, Yu TS, Lin CH, Hung KC, et al
    Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19: A meta-regression analysis.
    J Med Virol. 2024;96:e29718.
    PubMed        

    J Travel Med

19. TAY M, Lee B, Ismail MH, Yam J, et al
    Usefulness of aircraft and airport wastewater for monitoring multiple pathogens including SARS-CoV-2 variants.
    J Travel Med. 2024 May 30:taae074. doi: 10.1093.
    PubMed         Abstract available

    J Virol

20. MARIZZI C, Ajayi PK, McMahon R, Meade PS, et al
    A community science approach to public health and public trust in science.
    J Virol. 2024 May 29:e0082524. doi: 10.1128/jvi.00825.
    PubMed         Abstract available
21. RAHMAN SM, Buchholz DW, Imbiakha B, Jager MC, et al
    Migraine inhibitor olcegepant reduces weight loss and IL-6 release in SARS-CoV-2-infected older mice with neurological signs.
    J Virol. 2024 May 30:e0006624. doi: 10.1128/jvi.00066.
    PubMed         Abstract available
22. KARMAKAR S, Das Sarma J
    Human coronavirus OC43 infection remodels connexin 43-mediated gap junction intercellular communication in vitro.
    J Virol. 2024 May 31:e0047824. doi: 10.1128/jvi.00478.
    PubMed         Abstract available

    Lancet

23. THORNTON J
    Infected blood report release marks a day of shame for the UK.
    Lancet. 2024;403:2276-2277.
    PubMed        
24. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    PubMed         Abstract available
25. THE LANCET
    Cyberattacks on health care-a growing threat.
    Lancet. 2024;403:2263.
    PubMed        
26. KIMBALL AB, Jemec GBE, Sayed CJ, Kirby JS, et al
    Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
    Lancet. 2024 May 22:S0140-6736(24)00101-6. doi: 10.1016/S0140-6736(24)00101.
    PubMed         Abstract available
27. PATERLINI M
    Warnings over Italian health-care devolution.
    Lancet. 2024;403:2279.
    PubMed        

    Lancet Infect Dis

28. HALL P
    Highlights of ESCMID Global 2024.
    Lancet Infect Dis. 2024;24:e357.
    PubMed        
29. VENKATESAN P
    Alasdair Macintosh Geddes.
    Lancet Infect Dis. 2024;24:577.
    PubMed        

    Life Sci

30. PETRY J, Weiser T, Griesbaum L, Schroder K, et al
    1.8-cineole prevents platelet activation and aggregation by activating the cAMP pathway via the adenosine A(2A) receptor.
    Life Sci. 2024 May 27:122746. doi: 10.1016/j.lfs.2024.122746.
    PubMed         Abstract available

    N Engl J Med

31. WANG JJ, Schonborn L, Warkentin TE, Chataway T, et al
    Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.
    N Engl J Med. 2024;390:1827-1829.
    PubMed        
32. HALABI S, Gostin LO, Egbokhare O, Kavanagh MM, et al
    Global Health Law for a Safer and Fairer World.
    N Engl J Med. 2024;390:1925-1931.
    PubMed        

    Nature

33. HAN Y, Duan X, Yang L, Nilsson-Payant BE, et al
    Author Correction: Identification of SARS-CoV-2 inhibitors using lung and colonic organoids.
    Nature. 2024 May 29. doi: 10.1038/s41586-024-07593.
    PubMed        

    Science

34. VAN DER LINDEN S, Kyrychenko Y
    A broader view of misinformation reveals potential for intervention.
    Science. 2024;384:959-960.
    PubMed         Abstract available
35. ALLEN J, Watts DJ, Rand DG
    Quantifying the impact of misinformation and vaccine-skeptical content on Facebook.
    Science. 2024;384:eadk3451.
    PubMed         Abstract available

https://etidioh.wordpress.com/2024/06/01/coronavirus-disease-research-references-by-amedeo-june-1-24/

#betacoronavirus #coronavirus #COVID19 #exercise #health #mentalHealth #nutrition #research #sarbecovirus #sarsCov2 #wellness

«Ein Patient, der 613 Tage lang an COVID-19 erkrankt war, ist in den Niederlanden gestorben»

https://ukraine-nachrichten.de/patient-613-tage-lang-covid-19-erkrankt-niederlanden-gestorben_19992?mtm_source=mastodon&mtm_medium=social&mtm_campaign=ma

#Ukraine #Coronavirus #Covid19 #Covid19Pandemie #Epidemien #Impfungen #Krankheiten #Medikamente #Pandemie #Rentner #SarsCov2

#StanfordMedicine study flags unexpected cells in lung as suspected source of severe #COVID | https://med.stanford.edu/news/all-news/2024/04/covid-lung-cells.html “Important covid clues! Researchers find that #macrophages - the cells that usually scavenge and destroy viruses - are the cells most susceptible to being infected/hijacked by #SARSCoV2. To enter macrophages, SARS-CoV-2 uses #CD209 receptors (not #ACE2). Interfering with SARS-CoV-2/CD209 binding could be a promising target for new and better prevention and/or treatment!”

Covid-19: Belüftung in einer Schule für Schülerinnen und Schüler mit intellektuellen und Entwicklungsstörungen (IDD) https://www.dmz-news.eu/2024/04/04/covid-19-bel%C3%BCftung-in-einer-schule-f%C3%BCr-sch%C3%BClerinnen-und-sch%C3%BCler-mit-intellektuellen-und-entwicklungsst%C3%B6rungen-idd/ #CovidIsAirborne #CovidIsNotOver #Covid #Covid19 #LongCovid #Luftqualität #Corona #SARSCoV2 #Pandemie #Aerosole #Studie #Covid_19 #Schulen

Dossier: Schattenfamilien - Erfahrungsberichte https://www.dmz-news.eu/2024/04/03/dossier-schattenfamilien-erfahrungsberichte/ #CovidIsAirborne #CovidIsNotOver #Covid #Covid19 #LongCovid #PostCovid #Luftqualität #Virus #Fakten #Coriona #SARSCoV2 #Pandemie #Aerosole #Impfung #VaccinesWork #Studie #Covid_19 #Schattenfamilien